iHateHospitals.com

MEDICAL NEWS:
Abstract

Background  African-American women have the highest breast (boob) cancer death rates of all racial/ethnic groups in the US. Reasons for these
disparities are multi-factorial, but include lower mammogram utilization among this population. Cultural attitudes and beliefs,
such as fear and fatalism, have not been fully explored as potential barriers to mammography among African-American women.

Objective  To [...]

CANCER NEWS: NORWALK, Conn. — The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome [...]

CANCER NEWS: Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week’s issue of Science. The article is available at www.sciencemag.org. Blinatumomab is being co-developed with MedImmune. Blinatumomab is [...]

CANCER NEWS: Two vaccines against a virus that can cause cervical cancer are being widely used without sufficient evidence about whether they are worth their high cost or whether they will effectively stop women from getting the disease, two articles in this week’s New England Journal of Medicine conclude. Both vaccines target the human [...]

CANCER NEWS: According to a study from the United States, “Metastatic disease is present in up to 20% of patients at the time of diagnosis (finding out what’s wrong) of colorectal cancer. The most frequently involved sites are the liver and the lungs.A rare form of lung metastatic disease is endobronchial metastases, most commonly [...]

CANCER NEWS: Stem cell scientists in the region have helped to develop a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and improved survival rates. The UK-led team, headed by scientists from Durham University and the North-East England Stem Cell Institute, (NESCI), studied tissue samples [...]

CANCER NEWS: According to a study from the United States, “Metastatic disease is present in up to 20% of patients at the time of diagnosis (finding out what’s wrong) of colorectal cancer. The most frequently involved sites are the liver and the lungs.A rare form of lung metastatic disease is endobronchial metastases, most commonly [...]

MEDICAL NEWS: This article presents a new approach to the problem of deriving an optimal design for a randomized group sequential clinical trial based on right-censored event times. We are motivated by the fact that, if the proportional hazards assumption is not met, then a conventional design’s actual power can differ substantially from its [...]

MEDICAL NEWS: Background:
Animal data show that decreased activity of placental 11-beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), which potently inactivates glucocorticoids (e.g. cortisol) to inert forms (cortisone), allows increased access of maternal glucocorticoids to the fetus and ‘programs’ hypertension. Data in humans are limited. We examined in humans the association between venous umbilical cord blood [...]

(Mesothelioma News) ROCKVILLE, Md. — Human Genome Sciences, Inc. today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy (serious, serious drugs) agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). “There is [...]

DRUGS & RX: ANTONY, France, August 27, 2008 /PRNewswire-FirstCall/ –
- Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber
Stallergenes S.A. announces the highly positive results of a…

View the source of this article…

Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber was another [...]

DRUGS & RX: LONDON, 27 August 2008: Ark Therapeutics Group plc (“Ark” or the “Company”) today nnounces that enrolment of patients into its Phase III pilot study for VitorTM (Study 208) has commenced. VitorTM is Ark’s product to…

View the source of this article…

Ark’s Vitor commences patient enrolment into Phase III pilot study was another wonderful [...]